Supplementary Figure 2 from Remodeling of the Tumor Microenvironment Through PAK4 Inhibition Sensitizes Tumors to Immune Checkpoint Blockade

Abril-Rodriguez, Gabriel; Torrejon, Davis Y.; Karin, Daniel; Campbell, Katie M.; Medina, Egmidio; Saco, Justin D.; Galvez, Mildred; Champhekar, Ameya S.; Perez-Garcilazo, Ivan; Baselga-Carretero, Ignacio; Singh, Jas; Comin-Anduix, Begoña; Puig-Saus, Cristina; Ribas, Antoni

doi:10.1158/2767-9764.22545414.v1

crc-21-0133-s02.pdf (44.53 kB)

Supplementary Figure 2 from Remodeling of the Tumor Microenvironment Through PAK4 Inhibition Sensitizes Tumors to Immune Checkpoint Blockade

journal contribution

posted on 2023-04-04, 01:43 authored by Gabriel Abril-Rodriguez, Davis Y. Torrejon, Daniel Karin, Katie M. Campbell, Egmidio Medina, Justin D. Saco, Mildred Galvez, Ameya S. Champhekar, Ivan Perez-Garcilazo, Ignacio Baselga-Carretero, Jas Singh, Begoña Comin-Anduix, Cristina Puig-Saus, Antoni Ribas

Supplementary Figure 2: PAK4 deletion does not affect CCL21 secretion.

Funding

HHS | NIH | National Cancer Institute (NCI)

American Society of Clinical Oncology (ASCO)

V Foundation for Cancer Research (VFCR)

Ressler Family Foundation (The Ressler Family Foundation)

Parker Institute for Cancer Immunotherapy (Parker Institute)

History

ARTICLE ABSTRACT

Our findings provide new insights into PAK4 inhibition mechanism of action as well as the scientific foundation for specifically blocking PAK4 kinase activity using a novel and specific PAK4 kinase inhibitor to overcome resistance to PD-1 blockade.